FY2027 Earnings Forecast for argenex Issued By HC Wainwright

Key Points

• HC Wainwright raised argenx’s FY2027 EPS forecast to $34.82 from $34.38 and maintained a Buy rating with a $1,202 price target; it projects FY2028 EPS of $44.72.
• argenx’s latest quarterly results exceeded expectations, with EPS of $7.32 versus the $5.86 consensus and revenue of $1.54 billion versus estimates of $1.45 billion.
• Analyst sentiment remains broadly positive, with a consensus rating of “Moderate Buy” and an average price target of $1,118.28. Shares opened at $992.99, near their 52-week high, while institutional investors own 60.32% of the company.

argenex SE (NASDAQ:ARGX - Free Report) - Research analysts at HC Wainwright boosted their FY2027 EPS estimates for argenex in a note issued to investors on Tuesday, August 18th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings per share of $34.82 for the year, up from their previous forecast of $34.38. HC Wainwright currently has a "Buy" rating and a $1,202.00 price target on the stock. The consensus estimate for argenex's current full-year earnings is $28.77 per share. HC Wainwright also issued estimates for argenex's FY2028 earnings at $44.72 EPS.

argenex (NASDAQ:ARGX - Get Free Report) last posted its quarterly earnings results on Tuesday, July 21st. The company reported $7.32 EPS for the quarter, beating the consensus estimate of $5.86 by $1.46. The company had revenue of $1.54 billion for the quarter, compared to analyst estimates of $1.45 billion. argenex had a net margin of 32.19% and a return on equity of 43.59%.

Several other analysts have also commented on the company. Weiss Ratings lowered argenex from a "hold (c+)" rating to a "hold (c)" rating in a report on Thursday, July 23rd. Guggenheim initiated coverage on argenex in a report on Tuesday, August 4th. They issued a "buy" rating and a $1,185.00 price target for the company. Bank of America upped their price objective on argenex from $1,016.00 to $1,088.00 and gave the stock a "buy" rating in a research report on Thursday, July 2nd. Citigroup raised their price objective on shares of argenex from $1,152.00 to $1,182.00 and gave the stock a "buy" rating in a research note on Tuesday, July 21st. Finally, Oppenheimer lifted their target price on shares of argenex from $1,014.00 to $1,037.00 and gave the company an "outperform" rating in a report on Friday, July 24th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $1,118.28.

argenex Stock Up 0.5%

Shares of ARGX stock opened at $992.99 on Wednesday. The stock has a market cap of $62.12 billion, a PE ratio of 38.13, a price-to-earnings-growth ratio of 1.05 and a beta of 0.46. The business has a 50-day simple moving average of $886.02 and a 200-day simple moving average of $823.02. argenex has a 52-week low of $650.01 and a 52-week high of $1,009.75.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Whipplewood Advisors LLC acquired a new position in argenex during the first quarter worth $28,000. Eastern Bank acquired a new position in shares of argenex during the 2nd quarter worth about $32,000. Sunbelt Securities Inc. purchased a new position in argenex in the 3rd quarter valued at about $36,000. Axiom Investment Management LLC purchased a new position in argenex in the 1st quarter valued at about $50,000. Finally, WPG Advisers LLC boosted its holdings in argenex by 17.8% in the 1st quarter. WPG Advisers LLC now owns 86 shares of the company's stock worth $63,000 after buying an additional 13 shares during the last quarter. Hedge funds and other institutional investors own 60.32% of the company's stock.

Key Headlines Impacting argenex

Here are the key news stories impacting argenex this week:

• Positive Sentiment: argenx reported that its Phase 3 ALKIVIA trial of Vyvgart Hytrulo met its primary endpoint in autoimmune myositis. The result supports a potential label expansion for the drug and was followed by a sharp increase in the shares. ARGX Announces Positive Phase III Data on Vyvgart Hytrulo
• Positive Sentiment: Morgan Stanley said the myositis data strengthen the outlook for efgartigimod, the active ingredient in Vyvgart, and raised its price target for argenex SE from $1,200 to $1,230 while maintaining an “overweight” rating. Argenx's Myositis Data Strengthen Efgartigimod Outlook
• Positive Sentiment: Several firms lifted their targets after the trial update: Piper Sandler to $1,215, Wedbush to $1,150, RBC to $1,100, Truist to $1,095, HC Wainwright to $1,202 and Citizens JMP to $1,200. The upgrades generally retained bullish ratings, signaling greater expected upside and confidence in the commercial opportunity.
• Positive Sentiment: The analyst optimism helped ARGX hit a new 52-week high, with the stock opening near $993 versus a prior 52-week high of $1,009.75. argenex Hits New 1-Year High Following Analyst Upgrade
• Neutral Sentiment: Investors will likely focus next on regulatory and commercialization milestones for the myositis indication. Although analyst targets imply further upside, ARGX already trades near its 52-week high, making execution and valuation important considerations.

argenex Company Profile

argenx NASDAQ: ARGX is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx's research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company's lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source